Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$10.52 CAD
Change Today -0.08 / -0.75%
Volume 4.9K
COM On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
As of 3:59 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1441 CREEKSIDE DRIVE

6th Floor

Vancouver, BC V6J 4S7

Canada

Phone: 604-677-6905

Fax: 604-677-6915

Cardiome Pharma Corp., a specialty pharmaceutical company, is engaged in the development and commercialization of cardiovascular therapies. The company has two marketed, in-hospital, cardiology products, BRINAVESS and AGGRASTAT, which are commercially available in various markets outside of the United States. Products and Product Candidates BRINAVESS (vernakalant (IV)), was approved in the European Union in 2010 and is registered and approved in approximately 50 countries for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults (for non-surgery patients with atrial fibrillation of seven days or less) and for use in post-cardiac surgery patients with atrial fibrillation of three days or less. BRINAVESS is recommended as a first-line therapy in the European Society of Cardiology atrial fibrillation guidelines for the cardioversion of recent-onset atrial fibrillation in patients with no, or moderate, structural heart disease. AGGRASTAT (tirofiban HCL) is a reversible GP IIb/IIIa inhibitor (an intravenous anti-platelet drug) for use in Acute Coronary Syndrome (ACS) patients. The company acquired the ex-U.S. marketing rights to AGGRASTAT as part of the Correvio acquisition. Both BRINAVESS and AGGRASTAT are available commercially outside of the United States either directly through its own sales force in Europe or via its distributor and partner network in other parts of the world. Strategy The company’s core strategy is to create a hospital-based, profitable and sustainable pharmaceutical company through the acquisition, development and commercialization of innovative, cardiovascular products that the company believes would help patients, health care providers, and healthcare systems provide safer, more efficacious and cost effective treatments for heart disease. Main elements of its strategy include the following: expanding its product offering and product pipeline through in-licensing and/or acquisitions; successfully obtaining approval for vernakalant worldwide; successfully commercializing BRINAVESS in currently approved countries; continuing to support the worldwide marketing of AGGRASTAT; leveraging external resources; and continuing to support its pre-clinical programs in ion channel research by collaborating with external researchers many of whom have extensive knowledge and understanding of these programs. Competition The company’s competitors include Eli Lilly and Company; Johnson & Johnson/Centocor, Inc.; The Medicines Company; Merck & Co., Inc.; and MediCure Inc. History The company was founded in 1986. It was incorporated under the Company Act (British Columbia) in 1986. The company was formerly known as Nortran Resources Ltd. and changed its name to Nortran Pharmaceuticals Inc. in 1992. Further, the company changed its name to Cardiome Pharma Corp. in 2001.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COM:CN C$10.52 CAD -0.08

COM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COM.
View Industry Companies
 

Industry Analysis

COM

Industry Average

Valuation COM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.8x
Price/Book 8.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOME PHARMA CORP, please visit www.cardiome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.